^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GC007G

    i
    Other names: GC007G, donor-derived anti-CD19 chimeric antigen receptor cell therapy , Donor derived CD19-targeted CAR-T cell therapy, Donor CAR-19, Anti-CD19 Allo-CAR-T Cells
    Associations

    News

    Trials
    Company:
    AstraZeneca
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    12ms
    Donor-derived Anti-CD19 CAR T cells GC007g for relapsed or refractory B-cell acute lymphoblastic leukemia after allogeneic HSCT: a phase 1 trial. (PubMed, EClinicalMedicine)
    GC007g expanded and induced durable remission in patients with B-ALL relapsed after allo-HSCT, with manageable safety profiles. Gracell Biotechnologies Inc.
    P1 data • Journal • CAR T-Cell Therapy
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    GC007G
    over1year
    DONOR-DERIVED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE 1 TRIAL (EHA 2023)
    Donor-derived CD19 CAR T-cell expanded and induced durable remission in patients with B-ALL relapsed after allo-HSCT, with manageable safety profiles. Phase 2 clinical trial of GC007g is currently recruiting. B cell acute lymphoblastic leukemia, CAR-T
    P1 data • CAR T-Cell Therapy • IO biomarker
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    GC007G